Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma - Top-Institutions - MDSpire

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • By

  • Meera Mohan

  • Aniko Szabo

  • Heloise Cheruvalath

  • Anna Clennon

  • Vineel Bhatlapenumarthi

  • Anannya Patwari

  • Metodi Balev

  • Divaya Bhutani

  • Asis Shrestha

  • Sharmilan Thanendrarajan

  • Binod Dhakal

  • Maurizio Zangari

  • Anup Trikannad

  • Sruthi Vellanki

  • Samer Al-Hadidi

  • Suzanne Lentzsch

  • Frits van Rhee

  • Aishee Bag

  • Anita D’Souza

  • Nishi Shah

  • Rajshekhar Chakraborty

  • Mansi R. Shah

  • Carolina Schinke

  • April 23, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Columbia University Irving Medical Center
    Columbia University Irving Medical Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    University of Arkansas for Medical Sciences
    University of Arkansas for Medical Sciences

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Stem Cell Transplantation

  • #3

    Medical College of Wisconsin
    Medical College of Wisconsin

    Milwaukee, WI

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #4

    Rutgers Cancer Institute of New Jersey
    Rutgers Cancer Institute of New Jersey

    New Brunswick, NJ

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #5

    Montefiore Medical Center and Albert Einstein College of Medicine
    Montefiore Medical Center and Albert Einstein College of Medicine

    Bronx, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

Original Source(s)

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • by Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke

  • April 23, 2025

Related Content

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence